Arrowhead Pharmaceuticals Overview

  • Founded
  • 1989

Founded
  • Status
  • Public

  • Employees
  • 397

Employees
  • Stock Symbol
  • ARWR

Stock Symbol
  • Investments
  • 11

  • Share Price
  • $33.28

  • (As of Monday Closing)

Arrowhead Pharmaceuticals General Information

Description

Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.

Contact Information

Formerly Known As
InterActive Group, Arrowhead Research
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Stock Exchange
NAS
Primary Office
  • 177 East Colorado Boulevard
  • Suite 700
  • Pasadena, CA 91105
  • United States
+1 (626) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Arrowhead Pharmaceuticals Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$33.28 $33.61 $26.81 - $56.25 $3.79B 114M 1.01M -$1.67

Arrowhead Pharmaceuticals Financials Summary

In Thousands,
USD
TTM 30-Sep-2022 FY 2022 30-Sep-2022 FY 2021 30-Sep-2021 FY 2020 30-Sep-2020
EV 3,183,176 3,183,176 6,016,737 4,138,470
Revenue 243,231 243,231 138,287 87,992
EBITDA (167,321) (167,321) (138,699) (87,800)
Net Income (176,063) (176,063) (140,848) (84,553)
Total Assets 691,939 691,939 710,148 522,504
Total Debt 81,576 81,576 25,545 21,138
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Arrowhead Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Arrowhead Pharmaceuticals‘s full profile, request access.

Request a free trial

Arrowhead Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to tr
Biotechnology
Pasadena, CA
397 As of 2022
00.000
000000 - 000 00.000

000000

elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut eni
0000 000000000
Cambridge, MA
0000 As of 0000
00.000
0000 00.000

000000

olor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut
0000 000000000
San Diego, CA
000 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Arrowhead Pharmaceuticals Competitors (87)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Alnylam Pharmaceuticals Formerly VC-backed Cambridge, MA 0000 00.000 0000 00.000
000000000 00000000 Formerly VC-backed San Diego, CA 000 00000 000000000 00000
00000 000000000000 Corporate Backed or Acquired Carlsbad, CA 000 0000 00000000000 0000
0000 000000000000 Formerly VC-backed Cambridge, MA 000 00.000 000000000 00.000
00000000 000000000 Formerly VC-backed Waltham, MA 00 00000 00000000 00000
You’re viewing 5 of 87 competitors. Get the full list »

Arrowhead Pharmaceuticals Patents

Arrowhead Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20230013224-A1 Rnai agents for inhibiting expression of xanthine dehydrogenase (xdh), pharmaceutical compositions thereof, and methods of use Pending 21-Jun-2021 00000000000
US-20230002773-A1 Rnai agents for inhibiting expression of xanthine dehydrogenase (xdh), pharmaceutical compositions thereof, and methods of use Active 21-Jun-2021 00000000000
US-11549112-B1 Rnai agents for inhibiting expression of xanthine dehydrogenase (xdh), pharmaceutical compositions thereof, and methods of use Active 21-Jun-2021 00000000000 00
US-20230002767-A1 Rnai agents for inhibiting expression of mucin 5ac (muc5ac), compositions thereof, and methods of use Pending 28-May-2021 0000000000
US-20220396791-A1 Rnai agents for inhibiting expression of receptor for advanced glycation end-products, compositions thereof, and methods of use Pending 08-Apr-2021 C12N15/1138
To view Arrowhead Pharmaceuticals’s complete patent history, request access »

Arrowhead Pharmaceuticals Executive Team (16)

Name Title Board Seat Contact Info
Christopher Anzalone Ph.D Chief Executive Officer & Board Member
Kenneth Myszkowski Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Patrick O'Brien JD Chief Operating Officer, Operations & General Counsel, Legal
Tracie Oliver Chief Commercial Officer
Vincent Anzalone Vice President & Head of Investor Relations
You’re viewing 5 of 16 executive team members. Get the full list »

Arrowhead Pharmaceuticals Board Members (12)

Name Representing Role Since
000000 00000000 00 Self Board Member 000 0000
00000000000 000000 Arrowhead Pharmaceuticals Chief Executive Officer & Board Member 000 0000
00000000 00000 00 Self Chairman & Board Member 000 0000
00000000 00 000000 Self Board Member 000 0000
00000 0000000 00.0 Self Board Member 000 0000
You’re viewing 5 of 12 board members. Get the full list »

Arrowhead Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Arrowhead Pharmaceuticals Investments & Acquisitions (11)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000 00000 29-Apr-2022 00000 0000 0000 Drug Discovery
0000000(00000 25-Apr-2022 00000 0000 0000 Drug Discovery
00000000 (000 05-Mar-2015 0000000000 0000 Biotechnology 000000000
00000 0000000 11-Apr-2012 0000000000 000 Drug Discovery
Roche Holding (RNA Therapeutics Business) 24-Oct-2011 Merger/Acquisition 00.00 Drug Delivery 000000000
You’re viewing 5 of 11 investments and acquisitions. Get the full list »

Arrowhead Pharmaceuticals ESG

Risk Overview

Risk Rating

Updated December, 14, 2022

25.06 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 15,613

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 1,004

Rank

00.00

Percentile

Biotechnology

Subindustry

00 of 462

Rank

00.00

Percentile

To view Arrowhead Pharmaceuticals’s complete esg history, request access »

Arrowhead Pharmaceuticals Exits (5)

Company Name Exit Date Exit Type Exit Size Status Buyers
000000 01-Aug-2008 000000000000000000 00000 Completed
  • 000000000 00000000
000000 17-Jun-2008 00000 00000 00 000 Completed
  • 2 buyers
0000000 0000000000 16-Oct-2006 00000 00000 00 000.00 Completed
  • 2 buyers
0000000 0000000000 04-Jun-2004 000000000000000000 Completed
  • 000000000 00000000
Unidym Early Stage VC 000 Completed
To view Arrowhead Pharmaceuticals’s complete exits history, request access »